Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial-Reference-Cited by-同舟云学术

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Published:2008-11 Issue:9653 Volume:372 Page:1881-1893
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Buchbinder Susan P,Mehrotra Devan V,Duerr Ann,Fitzgerald Daniel W,Mogg Robin,Li David,Gilbert Peter B,Lama Javier R,Marmor Michael,del Rio Carlos,McElrath M Juliana,Casimiro Danilo R,Gottesdiener Keith M,Chodakewitz Jeffrey A,Corey Lawrence,Robertson Michael N

Publisher

Elsevier BV

Subject

General Medicine

Reference52 articles.

1. Progress and obstacles in the development of an AIDS vaccine;Letvin;Nat Rev Immunol,2006

2. HIV vaccines: new frontiers in vaccine development;Duerr;Clin Infect Dis,2006

3. HIV vaccine design and the neutralizing antibody problem;Burton;Nat Immunol,2004

4. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates;Haynes;Expert Rev Vaccines,2006

5. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination;Polonis;Virology,2008

Cited by 1466 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA-based HIV-1 vaccines;Clinical Microbiology Reviews;2024-09-12

2. HIV Vaccine Development at a Crossroads: New B and T Cell Approaches;Vaccines;2024-09-12

3. A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications;Molecular Therapy - Methods & Clinical Development;2024-09

4. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5;International Journal of Pharmaceutics;2024-09

5. Human Immunodeficiency Virus Vaccine;Infectious Disease Clinics of North America;2024-09